Market news

Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk. Duri

Alnylam Pharmaceuticals recently presented at Wells Fargo’s 21st Annual Healthcare Conference in Boston and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York, highlighting its RNA interference portfolio to investors and industry peers. These appearances coincided with a very large projected expansion of the global oligonucleotide therapeutics market to US$72.10 billions by 2035, underscoring Alnylam’s positioning as a key RNA-based medicines innovator. We’ll now examine...

Analysts think Alnylam could rebound strongly over the next 12 months.

American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

Alnylam Pharmaceuticals' (ALNY) zilebesiran product candidate could see a "significant commercial op

CAMBRIDGE, Mass., September 02, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success

CAMBRIDGE, Mass., August 30, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data exp

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals stock has fallen 46.8% over the past year, yet the valuation checks still flag it as leaning expensive rather than a clear bargain. With fresh clinical data on its RNAi programs coming at the ESC Congress 2026, investors are weighing that share price slump against what the current market valuation implies. The share price decline of 46.8% over the last 12 months signals that expectations have come down sharply and raises the question of whether sentiment has weakened...

Alnylam Pharmaceuticals (ALNY) has drawn market attention after announcing plans to present new clinical and real-world data on its ATTR and hypertension RNAi programs at the ESC Congress 2026 in Munich. See our latest analysis for Alnylam Pharmaceuticals. Despite the ESC Congress announcement, Alnylam Pharmaceuticals’ share price has been under pressure, with the stock down 41% year to date and the 1 year total shareholder return declining 47%, although the 3 year total shareholder return...

Alnylam Pharmaceuticals announced it will present new clinical and real-world data on AMVUTTRA (vutrisiran) and investigational hypertension drug zilebesiran at the European Society of Cardiology Congress 2026 in Munich, following the release of detailed HELIOS-B and KARDIA-3 study analyses. The breadth of ATTR and hypertension data, spanning late-stage trials and real-world evidence, reinforces Alnylam’s RNAi platform reach across serious cardiovascular conditions. We’ll now examine how...

CAMBRIDGE, Mass., August 24, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to the existing and growing body of evidence demonstrating strength in RNAi-powered transthyret

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on an annualized basis producing an average annual return of 15.23%. Currently, Alnylam Pharmaceuticals has a market